2,302
Views
1
CrossRef citations to date
0
Altmetric
Review

Single whole genome sequencing analysis blazes the trail for precision medicine

ORCID Icon, &
Pages 134-135 | Received 29 Nov 2021, Accepted 13 Dec 2021, Published online: 06 Feb 2022

References

  • Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the princess margaret IMPACT/COMPACT trial. Genome Med. 2016;8(1):109. DOI:10.1186/s13073-016-0364-2.
  • Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, et al. Personalized medicine in a phase I clinical trials program: the MD anderson cancer center initiative. Clin Cancer Res. 2012;18(22):6373–6383. DOI:10.1158/1078-0432.CCR-12-1627.
  • Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, Hamilton SR, Williams PM, Iafrate AJ, Sklar J, et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: national cancer institute molecular analysis for therapy choice (NCI-MATCH). J Clin Oncol. 2020;38(33):3883–3894. DOI:10.1200/JCO.19.03010.
  • Pich O, Muinos F, Lolkema MP, Steeghs N, Gonzalez-Perez A, Lopez-Bigas N. The mutational footprints of cancer therapies. Nat Genet. 2019;51(12):1732–1740. DOI:10.1038/s41588-019-0525-5.
  • van de Haar J, Hoes LR, Roepman P, Lolkema MP, Verheul HMW, Gelderblom H, de Langen AJ, Smit EF, Cuppen E, Wessels LFA, et al. Limited evolution of the actionable metastatic cancer genome under therapeutic pressure. Nat Med. 2021;27(9):1553–1563. DOI:10.1038/s41591-021-01448-w.
  • Einstein DJ, Arai S, Calagua C, Xie F, Voznesensky O, Capaldo BJ, Luffman C, Hecht JL, Balk SP, Sowalsky AG, et al. Metastatic castration-resistant prostate cancer remains dependent on oncogenic drivers found in primary tumors. JCO Precision Oncology. 2021;5(5):1514–1522. DOI:10.1200/po.21.00059.
  • Gomez K, Miura S, Huuki LA, Spell BS, Townsend JP, Kumar S. Somatic evolutionary timings of driver mutations. BMC Cancer. 2018;18(1):85. DOI:10.1186/s12885-017-3977-y.
  • Lin LH, Allison DHR, Feng Y, Jour, G, Park, K, Zhou, F, Moreira, AL, Shen, G, Feng, X et al, Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas. Mod Pathol. 2021;34(12):2168–2174. DOI:10.1038/s41379-021-00880-0.
  • Makarem M, Garcia-Pardo M, Leighl NB. Plasma-based genotyping in advanced solid tumors: a comprehensive review. Cancers (Basel). 2021;13(21):5299. DOI:10.3390/cancers13215299.
  • McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–628. DOI:10.1016/j.cell.2017.01.018.
  • Simeonov KP, Byrns CN, Clark ML, Norgard RJ, Martin B, Stanger BZ, Shendure J, McKenna A, Lengner CJ. Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell. 2021;39(8):1150–62 e9. DOI:10.1016/j.ccell.2021.05.005.
  • Longo SK, Guo MG, Ji AL, Khavari PA. Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics. Nat Rev Genet. 2021;22(10):627–644. DOI:10.1038/s41576-021-00370-8.